Maximize the Clinical & Commercial Opportunity of the Adenosine-Pathway as a Second-Generation Immuno-Oncology Target A plethora of showstopping clinical trial data readouts are being met with refreshed excitement, enthusiasm and R&D investment for adenosine-pathway targets, one of the most validated and established oncology pathways.
10-12 May 2022